Search

Polymetabolic syndrome achieved pandemic proportions and dramatically influenced public health systems functioning worldwide. Chronic vascular complications are the major contributors to increased morbidity, disability, and mortality rates in diabetes patients. Nitric oxide (NO) is among the most important vascular bed function regulators. However, NO homeostasis is significantly deranged in pathological conditions. Additionally, different hormones directly or indirectly affect NO production and activity and subsequently act on vascular physiology. In this paper, we summarize the recent literature data related to the effects of insulin, estradiol, insulin-like growth factor-1, ghrelin, angiotensin II and irisin on the NO regulation in physiological and diabetes circumstances.

Background: There are several antibiotic resistance genes (ARG) for the Escherichia coli (E. coli) bacteria that cause urinary tract infections (UTI), and it is therefore important to identify these ARG. Artificial Intelligence (AI) has been used previously in the field of gene expression data, but never adopted for the detection and classification of bacterial ARG. We hypothesize, if the data is correctly conferred, right features are selected, and Deep Learning (DL) classification models are optimized, then (i) non-linear DL models would perform better than Machine Learning (ML) models, (ii) leads to higher accuracy, (iii) can identify the hub genes, and, (iv) can identify gene pathways accurately. We have therefore designed aiGeneR, the first of its kind system that uses DL-based models to identify ARG in E. coli in gene expression data. Methodology: The aiGeneR consists of a tandem connection of quality control embedded with feature extraction and AI-based classification of ARG. We adopted a cross-validation approach to evaluate the performance of aiGeneR using accuracy, precision, recall, and F1-score. Further, we analyzed the effect of sample size ensuring generalization of models and compare against the power analysis. The aiGeneR was validated scientifically and biologically for hub genes and pathways. We benchmarked aiGeneR against two linear and two other non-linear AI models. Results: The aiGeneR identifies tetM (an ARG) and showed an accuracy of 93% with area under the curve (AUC) of 0.99 (p < 0.05). The mean accuracy of non-linear models was 22% higher compared to linear models. We scientifically and biologically validated the aiGeneR. Conclusions: aiGeneR successfully detected the E. coli genes validating our four hypotheses.

Due to the intricate relationship between the small non-coding ribonucleic acid (miRNA) sequences, the classification of miRNA species, namely Human, Gorilla, Rat, and Mouse is challenging. Previous methods are not robust and accurate. In this study, we present AtheroPoint’s GeneAI 3.0, a powerful, novel, and generalized method for extracting features from the fixed patterns of purines and pyrimidines in each miRNA sequence in ensemble paradigms in machine learning (EML) and convolutional neural network (CNN)-based deep learning (EDL) frameworks. GeneAI 3.0 utilized five conventional (Entropy, Dissimilarity, Energy, Homogeneity, and Contrast), and three contemporary (Shannon entropy, Hurst exponent, Fractal dimension) features, to generate a composite feature set from given miRNA sequences which were then passed into our ML and DL classification framework. A set of 11 new classifiers was designed consisting of 5 EML and 6 EDL for binary/multiclass classification. It was benchmarked against 9 solo ML (SML), 6 solo DL (SDL), 12 hybrid DL (HDL) models, resulting in a total of 11 + 27 = 38 models were designed. Four hypotheses were formulated and validated using explainable AI (XAI) as well as reliability/statistical tests. The order of the mean performance using accuracy (ACC)/area-under-the-curve (AUC) of the 24 DL classifiers was: EDL > HDL > SDL. The mean performance of EDL models with CNN layers was superior to that without CNN layers by 0.73%/0.92%. Mean performance of EML models was superior to SML models with improvements of ACC/AUC by 6.24%/6.46%. EDL models performed significantly better than EML models, with a mean increase in ACC/AUC of 7.09%/6.96%. The GeneAI 3.0 tool produced expected XAI feature plots, and the statistical tests showed significant p-values. Ensemble models with composite features are highly effective and generalized models for effectively classifying miRNA sequences.

Background: Carotid artery atherosclerosis is highly prevalent in the general population and is a well-established risk factor for acute ischemic stroke. Although the morphological characteristics of vulnerable plaques are well recognized, there is a lack of consensus in reporting and interpreting carotid plaque features. Objectives: The aim of this paper is to establish a consistent and comprehensive approach for imaging and reporting carotid plaque by introducing the Plaque–RADS (Reporting and Data System) score. Methods: A panel of experts recognized the necessity to develop a classification system for carotid plaque and its defining characteristics. Using a multimodality analysis approach, the Plaque-RADS categories were established through consensus, drawing on existing published reports. Results: The authors present a universal classification that is applicable to both researchers and clinicians. The Plaque-RADS score offers a morphological assessment in addition to the prevailing quantitative parameter of “stenosis.” The Plaque-RADS score spans from grade 1 (indicating complete absence of plaque) to grade 4 (representing complicated plaque). Accompanying visual examples are included to facilitate a clear understanding of the Plaque-RADS categories. Conclusions: Plaque-RADS is a standardized and reliable system of reporting carotid plaque composition and morphology via different imaging modalities, such as ultrasound, computed tomography, and magnetic resonance imaging. This scoring system has the potential to help in the precise identification of patients who may benefit from exclusive medical intervention and those who require alternative treatments, thereby enhancing patient care. A standardized lexicon and structured reporting promise to enhance communication between radiologists, referring clinicians, and scientists.

(1) Objective: Myocarditis can be associated with ventricular arrhythmia (VA), individual non-invasive risk stratification through cardiovascular magnetic resonance (CMR) is of great clinical significance. Our study aimed to explore whether left atrial (LA) and left ventricle (LV) myocardial strain serve as independent predictors of VA in patients with myocarditis. (2) Methods: This retrospective study evaluated CMR scans in 141 consecutive patients diagnosed with myocarditis based on the updated Lake Louise criteria (29 females, mean age 41 ± 20). The primary endpoint was VA; this encompassed ventricular fibrillation, sustained ventricular tachycardia, nonsustained ventricular tachycardia, and frequent premature ventricular complexes. LA and LV strain function were performed on conventional cine SSFP sequences. (3) Results: After a median follow-up time of 23 months (interquartile range (18–30)), 17 patients with acute myocarditis reached the primary endpoint. In the multivariable Cox regression analysis, LA reservoir (hazard ratio [HR] and 95% confidence interval [CI]: 0.93 [0.87–0.99], p = 0.02), LA booster (0.87 95% CI [0.76–0.99], p = 0.04), LV global longitudinal (1.26 95% CI [1.02–1.55], p = 0.03), circumferential (1.37 95% CI [1.08–1.73], p = 0.008), and radial strain (0.89 95% CI [0.80–0.98], p = 0.01) were all independent determinants of VA. Patients with LV global circumferential strain > −13.3% exhibited worse event-free survival compared to those with values ≤ −13.3% (p < 0.0001). (4) Conclusions: LA and LV strain mechanism on CMR are independently associated with VA events in patients with myocarditis, independent to LV ejection fraction, and late gadolinium enhancement location. Incorporating myocardial strain parameters into the management of myocarditis may improve risk stratification.

The challenges associated with diagnosing and treating cardiovascular disease (CVD)/Stroke in Rheumatoid arthritis (RA) arise from the delayed onset of symptoms. Existing clinical risk scores are inadequate in predicting cardiac events, and conventional risk factors alone do not accurately classify many individuals at risk. Several CVD biomarkers consider the multiple pathways involved in the development of atherosclerosis, which is the primary cause of CVD/Stroke in RA. To enhance the accuracy of CVD/Stroke risk assessment in the RA framework, a proposed approach involves combining genomic-based biomarkers (GBBM) derived from plasma and/or serum samples with innovative non-invasive radiomic-based biomarkers (RBBM), such as measurements of synovial fluid, plaque area, and plaque burden. This review presents two hypotheses: (i) RBBM and GBBM biomarkers exhibit a significant correlation and can precisely detect the severity of CVD/Stroke in RA patients. (ii) Artificial Intelligence (AI)-based preventive, precision, and personalized (aiP3) CVD/Stroke risk AtheroEdge™ model (AtheroPoint™, CA, USA) that utilizes deep learning (DL) to accurately classify the risk of CVD/stroke in RA framework. The authors conducted a comprehensive search using the PRISMA technique, identifying 153 studies that assessed the features/biomarkers of RBBM and GBBM for CVD/Stroke. The study demonstrates how DL models can be integrated into the AtheroEdge™–aiP3 framework to determine the risk of CVD/Stroke in RA patients. The findings of this review suggest that the combination of RBBM with GBBM introduces a new dimension to the assessment of CVD/Stroke risk in the RA framework. Synovial fluid levels that are higher than normal lead to an increase in the plaque burden. Additionally, the review provides recommendations for novel, unbiased, and pruned DL algorithms that can predict CVD/Stroke risk within a RA framework that is preventive, precise, and personalized.

Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans.

Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.

Background: Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD. Objective: This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP 3 ) framework benefiting the pharmaceutical paradigm. Method: The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdge TM 4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers. Conclusions: Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdge TM 4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm.

Cardiovascular disease (CVD) is the leading cause of mortality and disability in developed countries. According to WHO, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to major adverse cardiac and cerebral events. Early detection and care for individuals at high risk could save lives, alleviate suffering, and diminish economic burden associated with these diseases. Carotid artery disease is not only a well-established risk factor for ischemic stroke, contributing to 10%-20% of strokes or transient ischemic attacks (TIAs), but it is also a surrogate marker of generalized atherosclerosis and a predictor of cardiovascular events. In addition to diligent history, physical examination, and laboratory detection of metabolic abnormalities leading to vascular changes, imaging of carotid arteries adds very important information in assessing stroke and overall cardiovascular risk. Spanning from carotid intima-media thickness (IMT) measurements in arteriopathy to plaque burden, morphology and biology in more advanced disease, imaging of carotid arteries could help not only in stroke prevention but also in ameliorating cardiovascular events in other territories (e.g. in the coronary arteries). While ultrasound is the most widely available and affordable imaging methods, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), their combination and other more sophisticated methods have introduced novel concepts in detection of carotid plaque characteristics and risk assessment of stroke and other cardiovascular events. However, in addition to robust progress in usage of these methods, all of them have limitations which should be taken into account. The main purpose of this consensus document is to discuss pros but also cons in clinical, epidemiological and research use of all these techniques.

Computer-Assisted Diagnosis: Diabetes and Cardiovascular Disease brings together multifaceted information on research and clinical applications from an academic, clinical, bioengineering and bioinformatics perspective. The editors provide a stellar, diverse list of authors to explore this interesting field. Academic researchers, bioengineers, new investigators and students interested in diabetes and heart disease need an authoritative reference to reduce the amount of time spent on source-searching so they can spend more time on actual research and clinical application. This reference accomplishes this with contributions by authors from around the world. Provides valuable information for academic clinicians, researchers, bioengineers and industry on diabetes and cardiovascular disease Discusses the impact of diabetes on cardiovascular disease Covers statistical classification techniques and risk stratification

Cardiovascular and Coronary Artery Imaging, Volume One covers state-of-the-art approaches for automated non-invasive systems in early cardiovascular disease diagnosis. The book includes several prominent imaging modalities, such as MRI, CT and PET technologies. A special emphasis is placed on automated imaging analysis techniques, which are important to biomedical imaging analysis of the cardiovascular system. This is a comprehensive, multi-contributed reference work that details the latest developments in spatial, temporal and functional cardiac imaging. Takes an integrated approach to cardiovascular and coronary imaging, covering machine learning, deep learning and reinforcement learning approaches Covers state-of-the-art approaches for automated non-invasive systems for early cardiovascular disease diagnosis Provides a perspective on future cardiovascular imaging and highlights areas that still need improvement

Computer-Assisted Diagnosis: Diabetes and Cardiovascular Disease brings together multifaceted information on research and clinical applications from an academic, clinical, bioengineering and bioinformatics perspective. The editors provide a stellar, diverse list of authors to explore this interesting field. Academic researchers, bioengineers, new investigators and students interested in diabetes and heart disease need an authoritative reference to reduce the amount of time spent on source-searching so they can spend more time on actual research and clinical application. This reference accomplishes this with contributions by authors from around the world. Provides valuable information for academic clinicians, researchers, bioengineers and industry on diabetes and cardiovascular disease Discusses the impact of diabetes on cardiovascular disease Covers statistical classification techniques and risk stratification

Cardiovascular and Coronary Artery Imaging, Volume One covers state-of-the-art approaches for automated non-invasive systems in early cardiovascular disease diagnosis. The book includes several prominent imaging modalities, such as MRI, CT and PET technologies. A special emphasis is placed on automated imaging analysis techniques, which are important to biomedical imaging analysis of the cardiovascular system. This is a comprehensive, multi-contributed reference work that details the latest developments in spatial, temporal and functional cardiac imaging. Takes an integrated approach to cardiovascular and coronary imaging, covering machine learning, deep learning and reinforcement learning approaches Covers state-of-the-art approaches for automated non-invasive systems for early cardiovascular disease diagnosis Provides a perspective on future cardiovascular imaging and highlights areas that still need improvement

State of the Art in Neural Networks and Their Applications presents the latest advances in artificial neural networks and their applications across a wide range of clinical diagnoses. Advances in the role of machine learning, artificial intelligence, deep learning, cognitive image processing and suitable data analytics useful for clinical diagnosis and research applications are covered, including relevant case studies. The application of Neural Network, Artificial Intelligence, and Machine Learning methods in biomedical image analysis have resulted in the development of computer-aided diagnostic (CAD) systems that aim towards the automatic early detection of several severe diseases. State of the Art in Neural Networks and Their Applications is presented in two volumes. Volume 1 covers the state-of-the-art deep learning approaches for the detection of renal, retinal, breast, skin, and dental abnormalities and more. Includes applications of neural networks, AI, machine learning, and deep learning techniques to a variety of imaging technologies Provides in-depth technical coverage of computer-aided diagnosis (CAD), with coverage of computer-aided classification, Unified Deep Learning Frameworks, mammography, fundus imaging, optical coherence tomography, cryo-electron tomography, 3D MRI, CT, and more Covers deep learning for several medical conditions including renal, retinal, breast, skin, and dental abnormalities, Medical Image Analysis, as well as detection, segmentation, and classification via AI

State of the Art in Neural Networks and Their Applications presents the latest advances in artificial neural networks and their applications across a wide range of clinical diagnoses. Advances in the role of machine learning, artificial intelligence, deep learning, cognitive image processing and suitable data analytics useful for clinical diagnosis and research applications are covered, including relevant case studies. The application of Neural Network, Artificial Intelligence, and Machine Learning methods in biomedical image analysis have resulted in the development of computer-aided diagnostic (CAD) systems that aim towards the automatic early detection of several severe diseases. State of the Art in Neural Networks and Their Applications is presented in two volumes. Volume 1 covers the state-of-the-art deep learning approaches for the detection of renal, retinal, breast, skin, and dental abnormalities and more. Includes applications of neural networks, AI, machine learning, and deep learning techniques to a variety of imaging technologies Provides in-depth technical coverage of computer-aided diagnosis (CAD), with coverage of computer-aided classification, Unified Deep Learning Frameworks, mammography, fundus imaging, optical coherence tomography, cryo-electron tomography, 3D MRI, CT, and more Covers deep learning for several medical conditions including renal, retinal, breast, skin, and dental abnormalities, Medical Image Analysis, as well as detection, segmentation, and classification via AI

Cardiovascular and Coronary Artery Imaging, Volume One covers state-of-the-art approaches for automated non-invasive systems in early cardiovascular disease diagnosis. The book includes several prominent imaging modalities, such as MRI, CT and PET technologies. A special emphasis is placed on automated imaging analysis techniques, which are important to biomedical imaging analysis of the cardiovascular system. This is a comprehensive, multi-contributed reference work that details the latest developments in spatial, temporal and functional cardiac imaging. Takes an integrated approach to cardiovascular and coronary imaging, covering machine learning, deep learning and reinforcement learning approaches Covers state-of-the-art approaches for automated non-invasive systems for early cardiovascular disease diagnosis Provides a perspective on future cardiovascular imaging and highlights areas that still need improvement

Computer-Assisted Diagnosis: Diabetes and Cardiovascular Disease brings together multifaceted information on research and clinical applications from an academic, clinical, bioengineering and bioinformatics perspective. The editors provide a stellar, diverse list of authors to explore this interesting field. Academic researchers, bioengineers, new investigators and students interested in diabetes and heart disease need an authoritative reference to reduce the amount of time spent on source-searching so they can spend more time on actual research and clinical application. This reference accomplishes this with contributions by authors from around the world. Provides valuable information for academic clinicians, researchers, bioengineers and industry on diabetes and cardiovascular disease Discusses the impact of diabetes on cardiovascular disease Covers statistical classification techniques and risk stratification